ANI Pharmaceuticals, Inc. (ANIP) Director Sells $1,740,479.36 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Daniel Raynor sold 27,964 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $62.24, for a total transaction of $1,740,479.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Daniel Raynor also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 19th, Daniel Raynor sold 7,215 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.85, for a total transaction of $439,032.75.

ANI Pharmaceuticals stock opened at $57.06 on Friday. The company has a market capitalization of $694.65, a P/E ratio of 16.88 and a beta of 2.91. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39. ANI Pharmaceuticals, Inc. has a fifty-two week low of $42.23 and a fifty-two week high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.06. The business had revenue of $47.30 million during the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a negative net margin of 0.61% and a positive return on equity of 23.41%. The company’s quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.84 earnings per share. sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 5.17 EPS for the current year.

Several research firms have recently commented on ANIP. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, December 9th. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, TheStreet lowered shares of ANI Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $72.25.

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after acquiring an additional 35,722 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ANI Pharmaceuticals by 25.2% in the third quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock worth $22,297,000 after acquiring an additional 85,529 shares in the last quarter. Deutsche Bank AG grew its stake in shares of ANI Pharmaceuticals by 7.4% in the fourth quarter. Deutsche Bank AG now owns 159,957 shares of the specialty pharmaceutical company’s stock worth $10,308,000 after acquiring an additional 10,982 shares in the last quarter. Northern Trust Corp grew its stake in shares of ANI Pharmaceuticals by 5.2% in the second quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock worth $5,285,000 after acquiring an additional 5,599 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 868.2% in the third quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock worth $5,404,000 after acquiring an additional 94,002 shares in the last quarter. Institutional investors and hedge funds own 56.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/ani-pharmaceuticals-inc-anip-director-daniel-raynor-sells-27964-shares-of-stock.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply